through the Early Career Investigator Awards as well as the Distinguished Investigator Lecture, which is presented annually at the BSCR Autumn Meeting by a world-leading cardiovascular scientist. This year, which marked the 10th anniversary of these prestigious awards, we were delighted to be joined by Peter Marshall, Bernard's brother, and his wife Rita, for both the prize session and the society dinner at which they presented the awards. The BSCR is extremely grateful to the Marshall family for their significant support over the past 10 years which has enabled the society to particularly recognise and encourage the next generation of cardiovascular scientists.
In this regard, it seems timely to highlight the significant achievements of our previous Bernard and Joan Marshall Young Investigator Award (as it was known until 2017) winners. Dr. Alexander Lyon (2010) is a Senior Lecturer in Cardiology, Imperial College London, and Consultant Cardiologist at the Royal Brompton Hospital, where he is the theme leader for NIHR-funded heart failure research. Dr. Joseph Burgoyne (2011) is a Senior Lecturer at King's College London. Dr. Christine Cheung (2012) is an Assistant Professor at Lee Kong Chian School of M e d i c i n e , N a n y a n g Te c h n o l o g i c a l U n i v e r s i t y, Singapore, and member of the Executive Committee of the Stem Cell Society of Singapore. Dr patho-physiological roles of guanylyl cyclases (GCs) within the heart. Impaired nitric oxide (NO)/guanylyl cyclase (GC)/ cyclic guanosine-3′,5′-monophosphate (cGMP) signalling, along with upregulation of cyclic nucleotide-hydrolysing phosphodiesterase (PDE) isozymes, contributes to the pathogenesis of heart failure. However, the role of PDE2 has so far been relatively poorly investigated, and in his studies, Mr. Preedy showed that selective inhibition of PDE2 in mice using either a chemical or genetic approach preferentially enhances NO/GC/cGMP signalling, leading to preservation of cardiac structure and function in a pressure-overload heart failure model. These findings substantiate the suggestion that PDE2-targeting drugs could be a new and productive approach to target both left ventricular hypertrophy and failure. signature'. Doxorubicin is an anthracycline antitumour agent with dose-related cardiotoxicity in an unpredictable subset of patients. Dr. Timm's studies used hyperpolarised magnetic resonance imaging to detect early metabolic changes that characterise this condition and precede cardiac functional decline in a rat model. She also showed that 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR), an activator of AMPK that promotes mitochondrial biogenesis and fatty acid oxidation, rescued cardiac functional decline in experimental doxorubicin-induced heart failure. Dr. Francesco Mazzarotto, who is currently a Postdoctoral Fellow at the University of Florence, presented his recent work on genetic diagnosis using a novel metric that he called 'diagnostic effectiveness'-a score estimating the relative effectiveness of a given gene in a diagnostic panel for hypertrophic cardiomyopathy. Dr. Mazzarotto showed that next-generation sequencing allowed additional sensitivity in screening, but that this was achieved predominantly by focussing on genes incontrovertibly associated with hypertrophic cardiomyopathy or its mimics, with limited or no benefit from wider array of genes. We hope that you enjoy reading the short review articles contributed by all four of the Bernard and Joan Marshall Early Career Investigator Award finalists, relevant to their areas of research, published in this special issue of Cardiovascular Drugs and Therapy.
We were delighted to honour Professor Joseph Wu from Stanford University with the Bernard and Joan Marshall Distinguished Investigator Award. This award is presented annually to a researcher that in the opinion of the BSCR committee has made distinguished contributions to cardiovascular research over many years and exemplifies the highest academic and professional standards in our field. The Bernard and Joan Marshall Distinguished Investigator receives an honorarium and is invited to present a keynote lecture at the BSCR Autumn Meeting. Professor Wu graduated from Yale School of Medicine where he originally developed his love of research by combining cardiovascular pharmacology and imaging in large animal models. He subsequently trained in internal medicine and cardiology at the University of California Los Angeles, before undertaking a PhD in the Department of Molecular Pharmacology with Dr. Sanjiv Gambhir. Here he developed molecular imaging technology to track gene and cardiac stem cell therapy in vivo using bioluminescence or positron-emission tomography, studies that he still rates as among his favourites and a defining period in his development as a scientist. Professor Wu was appointed as an Instructor in Medicine at Stanford University in 2004 and rapidly progressed to his current position as Director of the Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology at the Stanford School of Medicine. His laboratory focusses on unravelling biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). Professor Wu believes that iPSC-derived cells can be used to integrate the thousands of genetic variants that influence tissue behaviour and disease development in individual patients, thus representing a powerful tool for clinical prediction and patient-specific studies. His main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop the 'clinical trial in a dish' concept, and (iv) implement precision cardiovascular medicine for disease prevention and treatment of patients. Professor Wu has published > 350 manuscripts with 37,000 citations and an H-index of 95 according to Google Scholar. His research achievements have led to numerous awards including the Presidential Early Career Award for Scientists and Engineers presented by President Obama (2010), the American Heart Association (AHA) Merit Award (2017), and the AHA Distinguished Scientist Award (2018). Professor Wu also received the inaugural AHA Joseph A. Vita Award (2015), which is presented to an investigator whose body of work published in the last 5 years has had transformative impact on basic, translational, or clinical cardiovascular research. Taken together, he is clearly a worthy recipient of the Bernard and Joan Marshall Distinguished Investigator Award. In his lecture, Professor Wu spoke about his pioneering work in 'Stem Cells and Genomics for Precision Medicine'. He began by discussing the advances in the field over the years, in particular the methodology for generating cardiomyocytes from human pluripotent stem cells, with the latest approaches now allowing > 90% cardiomyocyte purity following chemically defined differentiation from human pluripotent cells. He then discussed a number of cases and studies illustrating modelling of cardiac genetic disease in individual patients Professor Joseph Wu being presented with the Bernard and Joan Marshall Distinguished Lecturer Award by Peter Marshall using iPSCs, with powerful data illustrating disease mechanisms and potential further therapeutic options. In an impressive and exciting grand tour of the possibilities of this approach, Professor Wu also discussed cardiac toxicity prediction, using iPSC-derived cardiomyocytes as a proxy to mimic the behaviour of adult heart in response to a range of drugs. This approach has been used by Professor Wu's group for prediction of both electrical repolarisation abnormalities as a cause for arrhythmias as well as cardiovascular toxicities associated with anticancer drugs, including anthracyclines, and newer agents, such as tyrosine kinase inhibitors. The breadth of examples and the depth of the science presented by Professor Wu were the highlight of the meeting and beautifully showcased the power of this approach for advancing precision medicine.
